A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

@article{Tsimberidou2009API,
  title={A phase I clinical trial of darinaparsin in patients with refractory solid tumors.},
  author={Apostolia-Maria Tsimberidou and Luis H Camacho and Srdan Verstovsek and Chaan Ng and David S. Hong and Cynthia Uehara and Catalina Gutierrez and Shawn Daring and Jan Stevens and Philip B. Komarnitsky and Brian Schwartz and Razelle Kurzrock},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 14},
  pages={
          4769-76
        }
}
PURPOSE Darinaparsin, an organic arsenic, targets essential cell survival pathways. We determined the dose-limiting toxicity (DLT) and maximum tolerated dose of darinaparsin in patients with advanced cancer. EXPERIMENTAL DESIGN Patients with solid malignancies refractory to conventional therapies were treated with i.v. darinaparsin daily for 5 days every 4 weeks. The starting dose (78 mg/m(2)) escalated to 109, 153, 214, 300, 420, and 588 mg/m(2). A conventional "3 + 3" design was used… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry.

VIEW 1 EXCERPT
CITES BACKGROUND

Thiolated arsenicals in arsenic metabolism: Occurrence, formation, and biological implications.

VIEW 1 EXCERPT
CITES BACKGROUND

Glutathione S-conjugates as prodrugs to target drug-resistant tumors

VIEW 3 EXCERPTS
CITES BACKGROUND